CC BY-NC-ND 4.0 · Laryngorhinootologie 2019; 98(S 02): S221
DOI: 10.1055/s-0039-1685704
Poster
Endoscopy
Georg Thieme Verlag KG Stuttgart · New York

Self-expanding mometasone furoate releasing self-disintegrating sinus implant – Clinical experience intraoperatively and postoperative follow-up

A Martin
1  Helios-Amperklinikum Dachau, Dachau
,
C Werner
2  Helios-Amperklinikum, Dachau
,
SI Schmitz
2  Helios-Amperklinikum, Dachau
,
H Hagedorn
2  Helios-Amperklinikum, Dachau
› Author Affiliations
Fa. Intersect
Further Information

Publication History

Publication Date:
23 April 2019 (online)

Introduction:

Patients with polyposis nasi have a high recurrence rate and, in more frequent relapse surgeries, also increased postoperative complications. Alternative surgical methods such as paranasal sinus stents can reduce the rate of recurrence and postoperative side effects and shorten the duration of surgery.

Material/Methods:

Stents from the company Intersect, PROPEL ™ "Mini" and "Normal" are used. The patients (n = 10) had been pre-operated several times. After polypectomy, the stents are minimally invasively introduced by means of applicator system to assess whether the functioning is as stated by the manufacturer, found postoperatively fewer complications and subsequently the recurrence rate can be reduced.

Results:

The adapters and stents show no malfunction. The Op-time is not extended, after exercise, a time advantage. All stents show no dislocations. After 6 weeks, no parts of stents are visible. Prolonged postoperative pain does not show up. In the first 6 weeks there is no recurrence of the preoperative symptoms, also no recurrence of polyposis. After 8 weeks symptoms reappear at three patients.

Discussion:

With good application and tolerability of the stents, reduced intraoperative wound irritation, and lack of relapse polyposis during the described period, the stent may be a minimally invasive alternative to FESS. A tamponade can be omitted, thus avoiding postoperative pain. Whether the stent has a clinical-symptomatic advantage over the FESS, must show subsequent studies. The Op-time is shortened.